The 2025 Endpoints 11 list recognized transformative private biotech companies driving groundbreaking therapies and technologies. Startups like Chai Discovery focus on AI-driven drug design, Umoja Biopharma aims to overcome in vivo CAR-T barriers, and Candid Therapeutics accelerates treatments for autoimmune diseases through novel T-cell engagers. These emerging companies underscore the industry’s emphasis on next-generation modalities and computational innovation shaping the future of biotech.